A 4-year trial of simvastatin in the treatment of patients with heterozygous familial hypercholesterolemia

フォーマット:

論文

責任表示:

Kitatani, Masako ; Koizumi, Junji ; Inazu, Akihiro ; Kajinami, Kouji ; Mabuchi, Hiroshi ; 小泉, 順二 ; 稲津, 明広 ; 梶波, 康二 ; 馬渕, 宏

言語:

英語

出版情報:

Elsevier, 1996-01

著者名:

Kitatani, Masako

Koizumi, Junji

Inazu, Akihiro

Kajinami, Kouji

Mabuchi, Hiroshi

小泉, 順二

稲津, 明広

梶波, 康二

馬渕, 宏

続きを見る

掲載情報:

Topics in Catalysis

ISSN:

0011-393x      

巻:

57

通号:

1

開始ページ:

62

終了ページ:

71

バージョン:

publisher

概要:

金沢大学医薬保健研究域保健学系<br />A study was conducted to determine the clinical efficacy and tolerability of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase in seven patients with heterozygous familial hypercholester … olemia (FH) (defined as primary hypercholesterolemia with tendon xanthoma or primary hypercholesterolemia without tendon xanthomas and at least one first-degree relative with familial hypercholesterolemia). These patients were administrated 10 mg/d of simvastatin for up to 4 years. Simvastatin significantly reduced levels of both total cholesterol and low-density lipoprotein cholesterol during treatment; respective reduction rates were 28% and 34% after 1 month and 32% and 40% after 4 years. Serum high-density lipoprotein cholesterol levels slightly and insignificantly increased. Serum triglyseride levels fell significantly by 24% at month 6. After this study, all xanthomas had reduced in size. No adverse events related to simvastatin were observed. We conclude that long-term simvastatin therapy is clinically useful and well tolerated in patients with FH. Copyright © 1985 Published by Elsevier Inc. 続きを見る

URL:

http://hdl.handle.net/2297/00049722